RELEASE
ARTICLE
The FDA is requiring that a warning about a risk of nonarteritic anterior ischemic optic neuropathy (NAION) be added to the package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity), exenatide, liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and orforglipron (Foundayo) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound).1
NAION — NAION is caused by reduced blood flow to the optic nerve. It is a common cause of acute optic nerve injury in adults >50 years old (incidence is 2.3-10.2 cases per 100,000 person-years).2 Patients typically present with sudden, painless vision loss in one eye, accompanied by reduced visual acuity and visual field defects. Vision loss can be permanent.3 Patients with a history of NAION are at increased risk of recurrence.
MECHANISM — The mechanism by which GLP-1 receptor agonists increase the risk of NAION is unclear. It may involve rapid correction of hyperglycemia, but patients receiving GLP-1 receptor agonists usually have NAION risk factors, such as diabetes, obesity, cardiovascular disease, hypertension, hyperlipidemia, and obstructive sleep apnea (GLP-1 receptor agonists are FDA-approved for treatment of type 2 diabetes, weight management, obstructive sleep apnea, and cardiovascular risk reduction).3
BASIS FOR NEW WARNING — NAION has been reported with all currently available GLP-1 receptor agonists.4 The new warning was based on the results of a FDA-conducted metaanalysis of 126 randomized controlled trials that included a total of 134,253 patients that found a higher incidence of NAION in GLP-1 receptor agonist users than in nonusers (6.4 cases per 100,000 person-years vs 3.8 cases per 100,000 person-years with placebo or a non-GLP-1 receptor agonist glucose-lowering drug). A retrospective study of data from the FDA Sentinel System that included new users of GLP-1 receptor agonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors found that the risk of developing NAION with a GLP-1 receptor agonist was not statistically significantly higher compared with a SGLT2 inhibitor, but it was higher compared with a DPP-4 inhibitor (32 events with a GLP-1 receptor agonist vs 31 events with a SGLT2 inhibitor vs 26 events with a DPP-4 inhibitor).1
RECOMMENDATIONS — The new FDA warning advises clinicians to instruct patients receiving GLP-1 receptor agonists to immediately report sudden onset of acute, painless, decreased vision, visual field deficits, or other visual disturbances. Patients with suspected NAION should be promptly referred to an ophthalmologist; the benefits of continuing a GLP-1 receptor agonist should be weighed against the risk of NAION.1 The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society support the FDA's recommendations.5
- FDA Drug Safety Communication. FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition. November 9, 2026. Available at: https://bit.ly/3UFqz32. Accessed November 12, 2026.
- SW DeParis et al. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: a consensus statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology 2026; 133:1029. doi:10.1016/j.ophtha.2026.04.008
- OH Ababneh et al. Nonarteritic anterior ischemic optic neuropathy: review and update. Neurol Clin 2026; 44:169. doi:10.1016/j.ncl.2025.11.001
- JT Hathaway et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol 2024; 142:732. doi:10.1001/jamaophthalmol.2024.2296
- American Academy of Ophthalmology. Here's what you need to know about the FDA's new GLP-1 warning. News release. November 11, 2026. Available at: https://bit.ly/4zlhFWu. Accessed November 13, 2026.
